S19-279 Nanoparticles Containing Toll-Like Receptor Agonist for Enhanced Efficacy of Immune Checkpoint Blockade Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity. Qian Yin Mark Davis
S21-223 Blocking and Reversing Extracellular Vesicle-Driven Transcriptomic Transformation with Annexin V Treatment Stanford researchers led by Dr. Francis Blankenberg Derek Holman